150 related articles for article (PubMed ID: 17351344)
1. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.
Zhou L; Opalinska J; Verma A
Cell Cycle; 2007 Mar; 6(5):534-7. PubMed ID: 17351344
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.
Navas TA; Mohindru M; Estes M; Ma JY; Sokol L; Pahanish P; Parmar S; Haghnazari E; Zhou L; Collins R; Kerr I; Nguyen AN; Xu Y; Platanias LC; List AA; Higgins LS; Verma A
Blood; 2006 Dec; 108(13):4170-7. PubMed ID: 16940419
[TBL] [Abstract][Full Text] [Related]
3. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.
Katsoulidis E; Li Y; Yoon P; Sassano A; Altman J; Kannan-Thulasiraman P; Balasubramanian L; Parmar S; Varga J; Tallman MS; Verma A; Platanias LC
Cancer Res; 2005 Oct; 65(19):9029-37. PubMed ID: 16204077
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.
Navas T; Zhou L; Estes M; Haghnazari E; Nguyen AN; Mo Y; Pahanish P; Mohindru M; Cao T; Higgins LS; Platanias LC; List A; Verma A; Bhagat T; Gajavelli S; Kambhampati S
Leuk Lymphoma; 2008 Oct; 49(10):1963-75. PubMed ID: 18949619
[TBL] [Abstract][Full Text] [Related]
5. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
[TBL] [Abstract][Full Text] [Related]
6. Signal transduction inhibitors in treatment of myelodysplastic syndromes.
Bachegowda L; Gligich O; Mantzaris I; Schinke C; Wyville D; Carrillo T; Braunschweig I; Steidl U; Verma A
J Hematol Oncol; 2013 Jul; 6():50. PubMed ID: 23841999
[TBL] [Abstract][Full Text] [Related]
7. p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes.
Shahjahan M; Dunphy CH; Ewton A; Zu Y; Monzon FA; Rice L; Chang CC
Am J Clin Pathol; 2008 Oct; 130(4):635-41. PubMed ID: 18794058
[TBL] [Abstract][Full Text] [Related]
8. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Bachegowda L; Morrone K; Winski SL; Mantzaris I; Bartenstein M; Ramachandra N; Giricz O; Sukrithan V; Nwankwo G; Shahnaz S; Bhagat T; Bhattacharyya S; Assal A; Shastri A; Gordon-Mitchell S; Pellagatti A; Boultwood J; Schinke C; Yu Y; Guha C; Rizzi J; Garrus J; Brown S; Wollenberg L; Hogeland G; Wright D; Munson M; Rodriguez M; Gross S; Chantry D; Zou Y; Platanias L; Burgess LE; Pradhan K; Steidl U; Verma A
Cancer Res; 2016 Aug; 76(16):4841-4849. PubMed ID: 27287719
[TBL] [Abstract][Full Text] [Related]
9. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro.
Bouscary D; Chen YL; Guesnu M; Picard F; Viguier F; Lacombe C; Dreyfus F; Fontenay-Roupie M
Exp Hematol; 2000 Jul; 28(7):784-91. PubMed ID: 10907640
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
Zhou L; Nguyen AN; Sohal D; Ying Ma J; Pahanish P; Gundabolu K; Hayman J; Chubak A; Mo Y; Bhagat TD; Das B; Kapoun AM; Navas TA; Parmar S; Kambhampati S; Pellagatti A; Braunchweig I; Zhang Y; Wickrema A; Medicherla S; Boultwood J; Platanias LC; Higgins LS; List AF; Bitzer M; Verma A
Blood; 2008 Oct; 112(8):3434-43. PubMed ID: 18474728
[TBL] [Abstract][Full Text] [Related]
11. p38 Mitogen-activated protein kinase and hematologic malignancies.
Feng Y; Wen J; Chang CC
Arch Pathol Lab Med; 2009 Nov; 133(11):1850-6. PubMed ID: 19886722
[TBL] [Abstract][Full Text] [Related]
12. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
13. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes.
Shetty V; Mundle S; Alvi S; Showel M; Broady-Robinson L; Dar S; Borok R; Showel J; Gregory S; Rifkin S; Gezer S; Parcharidou A; Venugopal P; Shah R; Hernandez B; Klein M; Alston D; Robin E; Dominquez C; Raza A
Leuk Res; 1996; 20(11-12):891-900. PubMed ID: 9009245
[TBL] [Abstract][Full Text] [Related]
14. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplasia: differentiating neoplastic from nonneoplastic syndromes of ineffective hematopoiesis in dogs.
Blue JT
Toxicol Pathol; 2003; 31 Suppl():44-8. PubMed ID: 12597430
[TBL] [Abstract][Full Text] [Related]
16. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes.
Mundle SD; Reza S; Ali A; Mativi Y; Shetty V; Venugopal P; Gregory SA; Raza A
Cancer Lett; 1999 Jun; 140(1-2):201-7. PubMed ID: 10403560
[TBL] [Abstract][Full Text] [Related]
17. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes.
Parker JE; Mufti GJ
Int J Hematol; 2001 Jun; 73(4):416-428. PubMed ID: 11503955
[TBL] [Abstract][Full Text] [Related]
18. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
19. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis and prognostic factors in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Leuk Lymphoma; 2002 Feb; 43(2):257-60. PubMed ID: 11999555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
